FULCRUM THERAPEUTICS ($FULC) posted quarterly earnings results on Tuesday, February 25th. The company reported earnings of -$0.31 per share, beating estimates of -$0.33 by $0.02. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $FULC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
FULCRUM THERAPEUTICS Hedge Fund Activity
We have seen 54 institutional investors add shares of FULCRUM THERAPEUTICS stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP removed 5,845,956 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $20,870,062
- COWEN AND COMPANY, LLC removed 2,964,127 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $10,581,933
- TRV GP IV, LLC removed 2,343,154 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $11,012,823
- SUVRETTA CAPITAL MANAGEMENT, LLC added 2,155,675 shares (+182.3%) to their portfolio in Q4 2024, for an estimated $10,131,672
- FMR LLC removed 1,633,550 shares (-94.8%) from their portfolio in Q4 2024, for an estimated $7,677,685
- MPM BIOIMPACT LLC removed 1,444,851 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $5,158,118
- JEFFERIES FINANCIAL GROUP INC. removed 1,433,316 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $5,116,938
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
